| 臺大學術典藏 |
2022-02-21T02:04:34Z |
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
|
Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG; Ducreux M. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG; Jeng Y.-M.; Hsu C. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
|
Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
|
Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial
|
Kudo M.; Lim H.Y.; ANN-LII CHENG; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y. |
| 臺大學術典藏 |
2022-02-21T02:04:36Z |
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
|
Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG; Yang M.-H.; Hsu C. |
| 臺大學術典藏 |
2022-02-21T02:04:36Z |
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
|
Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Lin C.-C.; Chen Y.-J.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Lin C.-C.; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
YING-CHUN SHEN; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T02:51:55Z |
Evolution of systemic treatment for advanced hepatocellular carcinoma
|
Wu T.-C.; YING-CHUN SHEN; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T03:52:30Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
JIH-HSIANG LEE; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:33Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
JIH-HSIANG LEE; Chen H.-Y.; Hsu F.-M.; Chen J.-S.; Liao W.-Y.; Shih J.-Y.; Yu C.-J.; Chen K.-Y.; Tsai T.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:33Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; JIH-HSIANG LEE; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:34Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non�VSmall-cell Lung Cancer Patients
|
Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Liao W.-Y.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:34Z |
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
|
Liao B.-C.; Bai Y.-Y.; JIH-HSIANG LEE; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; JIH-HSIANG LEE; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:36Z |
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
|
Liao B.-C.; Lin C.-C.; JIH-HSIANG LEE; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:36Z |
Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients treated with first-line tyrosine kinase inhibitors
|
Chang I.-S.; Jiang S.S.; Yang J.C.-H.; Su W.-C.; Chien L.-H.; Hsiao C.-F.; JIH-HSIANG LEE; Chen C.-Y.; Chen C.-H.; Chang G.-C.; Wang Z.; Lo F.-Y.; Chen K.-Y.; Wang W.-C.; Chen Y.-M.; Huang M.-S.; Tsai Y.-H.; Su Y.-C.; Hsieh W.-S.; Shih W.-C.; Shieh S.-H.; Yang T.-Y.; Lan Q.; Rothman N.; Chen C.-J.; Chanock S.J.; Yang P.-C.; Hsiung C.A. |
| 臺大學術典藏 |
2022-02-21T03:52:36Z |
New data on clinical decisions in NSCLC patients with uncommon EGFR mutations
|
Wu T.; Hsiue E.H.; JIH-HSIANG LEE; Lin C.; Yang J.C. |
| 臺大學術典藏 |
2022-02-21T03:52:37Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; JIH-HSIANG LEE; Yang J.C.; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T. |
| 臺大學術典藏 |
2022-02-21T03:52:37Z |
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
|
Liao B.-C.; Lin C.-C.; JIH-HSIANG LEE; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:37Z |
Profile of the therascreen? EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer
|
Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:38Z |
Safety of gefitinib in non-small cell lung cancer treatment
|
Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:38Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Liao B.-C.; JIH-HSIANG LEE; Lin C.-C.; Chen Y.-F.; Chang C.-H.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:38Z |
High prevalence of the BIM deletion polymorphism in young female breast cancer in an East Asian country
|
Lin C.-H.; Shen C.-Y.; JIH-HSIANG LEE; Huang C.-S.; Yang C.-H.; Kuo W.-H.; Chang D.-Y.; Hsiung C.-N.; Kuo K.-T.; Chen W.-W.; Chen I.-C.; Wu P.-F.; Kuo S.-H.; Chen C.-J.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T03:52:39Z |
Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma
|
Weng M.-T.; Tung T.-H.; JIH-HSIANG LEE; Wei S.-C.; Lin H.-L.; Huang Y.-J.; Wong J.-M.; Luo J.; Sheu J.-C. |
| 臺大學術典藏 |
2022-02-21T03:52:39Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
JIH-HSIANG LEE; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; Ho C.-C.; Laio W.-Y.; Yang P.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:39Z |
Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer
|
Thomas A.; JIH-HSIANG LEE; Abdullaev Z.; Park K.-S.; Pineda M.; Saidkhodjaeva L.; Miettinen M.; Wang Y.; Pack S.D.; Giaccone G. |
| 臺大學術典藏 |
2022-02-21T03:52:40Z |
The janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo
|
JIH-HSIANG LEE; Park K.-S.; Alberobello A.T.; Kallakury B.; Weng M.-T.; Wang Y.; Giaccone G. |
| 臺大學術典藏 |
2022-02-21T03:52:40Z |
Role of CYB5A in pancreatic cancer prognosis and autophagy modulation
|
Giovannetti E.; Wang Q.; Avan A.; Funel N.; Lagerweij T.; JIH-HSIANG LEE; Caretti V.; Van Der Velde A.; Boggi U.; Wang Y.; Vasile E.; Peters G.J.; Wurdinger T.; Giaccone G. |
| 臺大學術典藏 |
2022-02-21T03:52:40Z |
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer
|
Chen J.-Q.; JIH-HSIANG LEE; Herrmann M.A.; Park K.-S.; Heldman M.R.; Goldsmith P.K.; Wang Y.; Giaccone G. |
| 臺大學術典藏 |
2022-02-21T03:52:41Z |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
|
Huang M.-H.; JIH-HSIANG LEE; Chang Y.-J.; Tsai H.-H.; Lin Y.-L.; Lin A.M.Y.; Yang J.C.H. |
| 臺大學術典藏 |
2022-02-21T03:52:41Z |
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells
|
Weng M.-T.; JIH-HSIANG LEE; Wei S.-C.; Li Q.; Shahamatdar S.; Hsu D.; Schetter A.J.; Swatkoski S.; Mannan P.; Garfield S.; Gucek M.; Kim M.K.H.; Annunziata C.M.; Creighton C.J.; Emanuele M.J.; Harris C.C.; Sheu J.-C.; Giaccone G.; Luo J. |
| 臺大學術典藏 |
2022-02-21T03:52:41Z |
Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer
|
JIH-HSIANG LEE; Giovannetti E.; Hwang J.-H.; Petrini I.; Wang Q.; Voortman J.; Wang Y.; Steinberg S.M.; Funel N.; Meltzer P.S.; Wang Y.; Giaccone G. |
| 臺大學術典藏 |
2022-02-21T03:52:42Z |
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors
|
Voortman J.; JIH-HSIANG LEE; Killian J.K.; Suuriniemi M.; Wang Y.; Lucchi M.; Smith Jr. W.I.; Meltzer P.; Wang Y.; Giaccone G. |
| 臺大學術典藏 |
2022-02-21T03:52:42Z |
MicroRNA expression and clinical outcome of small cell lung cancer
|
JIH-HSIANG LEE; Voortman J.; Dingemans A.-M.C.; Voeller D.M.; Pham T.; Wang Y.; Giaccone G. |
| 臺大學術典藏 |
2022-02-21T03:52:42Z |
Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations
|
Wu S.-G.; Yang C.-H.; Yu C.-J.; JIH-HSIANG LEE; Hsu Y.-C.; Chang Y.-L.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2022-02-21T03:52:43Z |
Multifocal primary cutaneous CD30+ anaplastic large cell lymphoma responsive to thalidomide: The molecular mechanism and the clinical application
|
JIH-HSIANG LEE; Cheng A.-L.; Lin C.-W.; Kuo S.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:43Z |
Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer
|
JIH-HSIANG LEE; Yu C.-J.; Chen K.-Y.; Shih J.-Y.; Lin Y.-L.; Yang C.-H. |
| 臺大學術典藏 |
2022-02-21T06:00:15Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo, Jhe-Cyuan; Lin, Chen-Yuan; Lin, Chia-Chi; Huang, Ta-Chen; Lien, Ming-Yu; Lu, Li-Chun; HUNG-YANG KUO; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-02-21T07:13:01Z |
Attitude and behavior toward bystander cardiopulmonary resuscitation during COVID-19 outbreak
|
Chong, Kah-Meng; Chen, Jiun-Wei; Lien, Wan-Ching; Yang, Mei-Fen; Wang, Hui-Chih; Liu, Sot Shih-Hung; YEN-PIN CHEN; Chi, Chien-Yu; Wu, Marvin Chih-Hsien; Wu, Cheng-Yi; Liao, Edward Che-Wei; Huang, Edward Pei-Chuan; He, Hsien-Chin; Yang, Hsiang-Wen; Huang, Chien-Hua; Ko, Patrick Chow-In |
| 臺大學術典藏 |
2022-02-21T07:16:19Z |
Disease Concept-Embedding Based on the Self-Supervised Method for Medical Information Extraction from Electronic Health Records and Disease Retrieval: Algorithm Development and Validation Study
|
YEN-PIN CHEN; Lo, Yuan-Hsun; Lai, Feipei; Huang, Chien-Hua |
| 臺大學術典藏 |
2022-02-21T07:26:36Z |
Modified Bidirectional Encoder Representations From Transformers Extractive Summarization Model for Hospital Information Systems Based on Character-Level Tokens (AlphaBERT): Development and Performance Evaluation
|
YEN-PIN CHEN; Chen, Yi-Ying; Lin, Jr-Jiun; Huang, Chien-Hua; Lai, Feipei |
| 臺大學術典藏 |
2022-02-21T07:29:53Z |
Using a smartwatch with real-time feedback improves the delivery of high-quality cardiopulmonary resuscitation by healthcare professionals
|
Lu, Tsung-Chien; Chang, Yao-Ting; Ho, Te-Wei; Chen, Yi; Lee, Yi-Ting; Wang, Yu-Siang; YEN-PIN CHEN; Tsai, Chu-Lin; Ma, Matthew Huei-Ming; Fang, Cheng-Chung; Lai, Feipei; Meischke, Hendrika W; Turner, Anne M |
| 臺大學術典藏 |
2022-02-21T07:31:37Z |
A novel depth estimation algorithm of chest compression for feedback of high-quality cardiopulmonary resuscitation based on a smartwatch
|
Lu, Tsung-Chien; Chen, Yi; Ho, Te-Wei; Chang, Yao-Ting; Lee, Yi-Ting; Wang, Yu-Siang; YEN-PIN CHEN; Fu, Chia-Ming; Chiang, Wen-Chu; Ma, Matthew Huei-Ming; Fang, Cheng-Chung; Lai, Feipei; Turner, Anne M |
